Bright Path Labs
Revolutionizing Life-Saving Drug
Development Through Innovation,
Technology, And Sustainability.
Healthcare Crisis
Prescription drug prices are rising beyond the affordability of many Americans because of the length and complexity of the regulatory process and the scarcity of critical components of many life-saving medicines. One significant reason: 80% of the key ingredient supply chain is controlled by China, India, and others, leaving every American vulnerable to an increasingly unstable world.
“Now is the right time to take action to keep the U.S. drug supply chain secure and resilient.”
– Janet Woodcock, FDA’s Acting Commissioner
Bright Path Labs, Inc. is a leading U.S.-based advanced drug development and manufacturing company that has definitively answered the call to dramatically recast America’s reliance on foreign pharmaceutical ingredients and medicines using patented AI-enabled continuous flow technology.
Founded in 2017, Bright Path Labs’ game-changing platform drives rapid synthetic route development and highly automated, controlled, and inexpensive deployment of scaled cGMP commercial manufacturing. This unique technical capability also affordably and efficiently produces small batches of specialized medicines and orphan drugs to treat patients with rare diseases.
